- Conditions
- Osteoporosis
- Interventions
- Apomine
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • West Haverstraw, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 54,906
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo
- Biological · Dietary Supplement
- Lead sponsor
- Diamyd Medical AB
- Industry
- Eligibility
- 12 Years to 28 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Newport Beach, California • Palo Alto, California • San Diego, California + 10 more
- Conditions
- CGA
- Interventions
- CGA, control
- Behavioral · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Surgical Site Infection in Obese Women Undergoing C-section
- Interventions
- cephalexin & metronidazole, placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 13 Years and older · Female only
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Interventions
- Lutetium [177Lu] oxodotreotide/dotatate
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2034
- U.S. locations
- 3
- States / cities
- Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania
- Conditions
- Fabry Disease
- Interventions
- PRX-102 1 mg/kg every two weeks
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
- Conditions
- Trauma, Trauma Injury, Pain, Acute
- Interventions
- Bupivacaine Liposome Injection, Bupivacaine
- Drug
- Lead sponsor
- Chadrick Evans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- Dronedarone (SR33589), placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Progressive Cognitive Decline
- Interventions
- florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more
- Conditions
- Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
- Interventions
- Vehicle of TP-03
- Drug
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Northridge, California • Shelby, North Carolina
- Conditions
- Patients Who Have Failed Conventional DPEJ Placement
- Interventions
- DBE PEJ placement
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Interventions
- FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 508
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Etanercept, CHS-0214
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 647 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more
- Conditions
- Opioid-use Disorder, Chronic Pain Syndrome
- Interventions
- Naloxone Hydrochloride, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
- Interventions
- Ibrutinib, Lenalidomide, Rituximab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Healthy Volunteers
- Interventions
- Spire Health Monitor
- Device
- Lead sponsor
- Spire, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Louisville, Colorado
- Conditions
- Lung Cancer
- Interventions
- Sorafenib, Placebo
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 141
- States / cities
- Stanford, California • Aurora, Colorado • Boulder, Colorado + 103 more
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose, Standard Medical Care (SMC)
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Relapsed Sarcomas
- Interventions
- Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil)
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Quality of Life
- Interventions
- Personal Fitness Device
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Kenner, Louisiana • Baltimore, Maryland + 2 more
- Conditions
- Lung Cancer
- Interventions
- Gemcitabine, Carboplatin, Paclitaxel, Radiation
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Intradialytic Hypertension
- Interventions
- Carvedilol vs. Prazosin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Bladder Carcinoma
- Interventions
- Polyethylene Glycol Hydrogel
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington